Company logo

ROIV - Roivant Sciences Ltd.

NASDAQ -> Healthcare -> Biotechnology
London, United Kingdom
Type: Equity

ROIV price evolution
ROIV
(in millions $) 30 Jul 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Current assets
Cash
Short term investments
Net receivables $44.29 $54.6 $39.91
Inventory $5.24 $4.9 $4.22
Total current assets $6806.73 $1551.6 $1561.16
Long term investments
Property, plant & equipment $68.75 $73.1 $87.9
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $7312.68 $2065.5 $2136.65
Current liabilities
Accounts payable $35.23 $44.1 $50.03
Deferred revenue
Short long term debt
Total current liabilities $244.9 $265.5 $245
Long term debt $403.34 $389.4 $385.07
Total noncurrent liabilities
Total debt
Total liabilities $1222.92 $1117 $1225.92
Shareholders' equity
Retained earnings $727.29 -$4368.9 -$4064.57
Other shareholder equity -$27.78 -$3.1 -$6.61
Total shareholder equity
(in millions $) 1 May 2023 1 May 2022 1 May 2021 1 May 2020
Current assets
Cash $1.7 $1.7
Short term investments
Net receivables $32.73 $13.83 $15.28
Inventory $2.76
Total current assets $1798.59 $2146.52 $2186.99 $2219.24
Long term investments
Property, plant & equipment $92.34 $86.95 $77.03 $73.93
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $2389.6 $2585.13 $2589.69 $2477.05
Current liabilities
Accounts payable $37.83 $34.58 $20.55 $10.31
Deferred revenue
Short long term debt
Total current liabilities $272.45 $184.37 $218.96 $92.12
Long term debt $379.09 $210.02 $170.28 $108.59
Total noncurrent liabilities
Total debt
Total liabilities $1231.84 $523.7 $791.9 $444.89
Shareholders' equity
Retained earnings -$3772.75 -$2763.72 -$1918.46 -$1109.23
Other shareholder equity -$2.62 $403.54 -$98.56 -$2.35
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue $12.53 $4.32
Cost of revenue
Gross Profit $8.89 $2.59
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $289.66 $284.9 $140.45
Operating income
Income from continuing operations
EBIT
Income tax expense $2.17 $4
Interest expense -$57.34 -$25.18 $1.48
Net income
Net income -$291.59 -$331.81 -$270.06
Income (for common shares)
(in millions $) 1 May 2022 1 May 2021 1 May 2020
Revenue
Total revenue $55.29 $23.8 $67.69
Cost of revenue
Gross Profit -$413.82 $21.74 $66.56
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $432.07 $1092.63 $598.98
Operating income
Income from continuing operations
EBIT
Income tax expense $0.37 $1.69 $7.12
Interest expense $7.04 $90.39 -$147.08
Net income
Net income -$845.26 -$809.23 $1200.51
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$154.31 -$7.46 $303.3 $309
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $134.63 $141.98 $306.79 $305.72
Effect of exchange rate
Change in cash and equivalents -$461.39 -$117.56 -$67.64 $84.46
(in millions $) 1 May 2022 1 May 2021 1 May 2020
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $303.3 -$31.7 $1694.79
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $306.79 $456.26 $214.08
Effect of exchange rate
Change in cash and equivalents -$67.64 -$127.58 $1150.12
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Quick ratio N/A